Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?

2016 ◽  
Vol 23 (5) ◽  
pp. 948-957 ◽  
Author(s):  
B. S. Ye ◽  
W. W. Lee ◽  
J. H. Ham ◽  
J. J. Lee ◽  
P. H. Lee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Uric Acid ◽  
Cognitive Decline ◽  
Serum Uric Acid ◽  
Disease Biomarker

P3-098: Serum uric acid, cerebrospinal fluid marker of Alzheimer's disease and cognition

2015 ◽  
Vol 11 (7S_Part_14) ◽  
pp. P657-P658
Author(s):  
Byoung Seok Ye ◽  
Young H. Sohn ◽  
Jee Hyun Ham ◽  
Jae Jung Lee ◽  
Won Woo Lee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Uric Acid ◽  
Serum Uric Acid

scholarly journals Effects of Risperidone and Galantamine Treatment on Alzheimer’s Disease Biomarker Levels in Cerebrospinal Fluid

2017 ◽  
Vol 57 (2) ◽  
pp. 387-393 ◽  
Author(s):  
Victor Bloniecki ◽  
Dag Aarsland ◽  
Kaj Blennow ◽  
Jeffrey Cummings ◽  
Farshad Falahati ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Disease Biomarker

P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?

2015 ◽  
Vol 11 (7S_Part_7) ◽  
pp. P340-P340
Author(s):  
Henrietta Wellington ◽  
Ulrika Törnqvist ◽  
Erik Portelius ◽  
Ross W. Paterson ◽  
Nadia K. Magdalinou ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Neurodegenerative Diseases ◽  
Synaptic Protein ◽  
Disease Biomarker

Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline

2010 ◽  
Vol 19 (4) ◽  
pp. 1143-1148 ◽  
Author(s):  
Cristoforo Comi ◽  
Miryam Carecchio ◽  
Annalisa Chiocchetti ◽  
Stefania Nicola ◽  
Daniela Galimberti ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cognitive Decline

scholarly journals Alzheimer's Disease Biomarker Profile in Cerebrospinal Fluid of Individuals with Immune-Mediated Encephalitis

2016 ◽  
Vol 64 (9) ◽  
pp. e29-e31
Author(s):  
Marcos Fernandez Suarez ◽  
Ezequiel I. Surace ◽  
Miguel Riudavets ◽  
Martin Nogues ◽  
Silvia Vazquez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Disease Biomarker ◽  
Immune Mediated

Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer’s Disease

2020 ◽  
Vol 77 (3) ◽  
pp. 1143-1155
Author(s):  
Daniela Enache ◽  
Joana B. Pereira ◽  
Vesna Jelic ◽  
Bengt Winblad ◽  
Per Nilsson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Depressive Symptoms ◽  
Cognitive Decline ◽  
Lewy Bodies ◽  
Lewy Body Dementia ◽  
Synaptic Proteins ◽  
Subjective Cognitive Decline

Background: Cognitive deficits arising in the course of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and Parkinson’s disease with dementia (PDD) are directly linked to synaptic loss. Postmortem studies suggest that zinc transporter protein 3 (ZnT3), AMPA glutamate receptor 3 (GluA3), and Dynamin1 are associated with cognitive decline in AD and Lewy body dementia patients. Objective: We aimed to evaluate the diagnostic value of ZnT3, GluA3, and Dynamin 1 in the cerebrospinal fluid (CSF) of patients with dementia due to AD, DLB, and PDD compared to cognitively normal subjective cognitive decline (SCD) patients in a retrospective study. In addition, we assessed the relationship between synaptic markers and age, sex, cognitive impairment, and depressive symptoms as well as CSF amyloid, phosphorylated tau (p-tau), and total tau (T-tau). Methods: Commercially available ELISA immunoassay was used to measure the levels of proteins in a total of 97 CSF samples from AD (N = 24), PDD (N = 18), DLB (N = 27), and SCD (N = 28) patients. Cognitive impairment was assessed using the Mini-Mental State Examination (MMSE). Results: We found a significant increase in the concentrations of ZnT3, GluA3, and Dynamin1 in AD (p = 0.002) and of ZnT3 and Dynamin 1 in DLB (p = 0.001, p = 0.002) when compared to SCD patients. Changes in ZnT3 concentrations correlated with MMSE scores in AD (p = 0.011), and with depressive symptoms in SCD (p = 0.041). Conclusion: We found alteration of CSF levels of synaptic proteins in AD, PDD, and DLB. Our results reveal distinct changes in CSF concentrations of ZnT3 that could reflect cognitive impairment in AD with implications for future prognostic and diagnostic marker development.

scholarly journals Association between NME8 Locus Polymorphism and Cognitive Decline, Cerebrospinal Fluid and Neuroimaging Biomarkers in Alzheimer's Disease

PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e114777 ◽  
Author(s):  
Ying Liu ◽  
Jin-Tai Yu ◽  
Hui-Fu Wang ◽  
Xiao-Ke Hao ◽  
Yu-Fen Yang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cognitive Decline ◽  
Neuroimaging Biomarkers

Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia

2012 ◽  
Vol 33 (24) ◽  
pp. 3738-3744 ◽  
Author(s):  
Valentina Albertini ◽  
Luisa Benussi ◽  
Anna Paterlini ◽  
Michela Glionna ◽  
Annapaola Prestia ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cognitive Decline ◽  
Amyloid Beta ◽  
Amyloid Beta Peptide ◽  
Beta Peptide
Sign in / Sign up

Export Citation Format

Share Document